FINWIRES · TerminalLIVE
FINWIRES

C.banner International Grants 249.2 Million Options Under Incentive Scheme

By

C.banner International (HKG:1028) granted a little over 249.2 million options to certain grantees on Friday, according to a same-day Hong Kong bourse filing.

The options are exercisable into the same number of shares, representing 10% of the clothes retailer's issued shares, at HK$0.99 apiece.

Of the total, 24.9 million options each were granted to President Yuan Zhenhua and Chief Financial Officer Zhang Baojun, with the remaining 199.4 million options to 11 other employees.

The firm now has no shares available for future grant under the scheme.

Related Articles

Asia

China Securities Regulator Penalizes Three Brokers for Illegal Overseas Stock Trading

The China Securities Regulatory Commission sanctioned three brokers for illegally facilitating overseas securities trading for domestic investors, according to a Friday statement by the watchdog.Tiger Brokers (NZ), Futu Securities International (Hong Kong), and Longbridge Securities (Hong Kong) will have their ill-gotten claims confiscated and face "severe penalties," the regulator said."Such illegal cross-border business operations have disrupted the market order and should be subjected to a heavy crackdown," the securities regulator said.CSRC's move is seen to crack down on illegal outflows and regulate market misconduct, the South China Morning Post reported separately.

$^SSEC$^SZSE
Asia

Kelun Biotech to Present Study Results of Cancer Drugs at American Oncology Meeting

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) will present the results of its registrational studies on sacituzumab tirumotecan (sac-TMT) and lunbotinib fumarate at the 2026 American Society of Clinical Oncology annual meeting, according to a filing by parent Sichuan Kelun Pharmaceutical (SHE:002422) with the Shenzhen bourse.Its study on its sacituzumab tirumotecan drug versus pembrolizumab for advanced non-small cell lung cancer treatment showed a higher response rate for its sac-TMT against pembrolizumab, the filing said.The company will also present results from its study on lunbotinib, which showed an objective response rate of 87.1% on patients with RET-fusion positive non-small cell lung cancer in patients with prior chemotherapy.

$HKG:6990$SHE:002422
Asia

Market Chatter: Indonesia to Offer Flexibility for US Exports Under Earning Retention Policy

Indonesia is easing rules requiring natural resource explorers to retain a portion of their earnings in state-owned banks for mining exports to the US, among other countries, The Jakarta Globe reported Thursday, citing a senior official.Under a new policy, the state is requiring businesses to place 100% earnings into state-owned banks for at least a year, except firms in the oil sector, which need to park 30% for a minimum of three months.However, companies exporting to nations with trade agreements or a mutual understanding with Indonesia will see some flexibility, the report said, citing Chief Economic Affairs Minister Airlangga Hartarto.They will be required to put 30% of the proceeds for at least three months in state or certain non-state banks fitting specific criteria, the report quoted Airlangga as saying.Airlangga identified the U.S. as a trade partner eligible for the exemptions without naming any others. The two nations had signed a tariff deal in February, according to the report.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$^JKSE